Lowe Brockenbrough & Co. Inc. boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.0% in the second quarter, Holdings Channel reports. The institutional investor owned 107,921 shares of the company’s stock after acquiring an additional 2,076 shares during the period. Johnson & Johnson comprises approximately 1.9% of Lowe Brockenbrough & Co. Inc.’s investment portfolio, making the stock its 8th biggest holding. Lowe Brockenbrough & Co. Inc.’s holdings in Johnson & Johnson were worth $13,095,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Massachusetts Financial Services Co. MA raised its position in Johnson & Johnson by 1.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 30,303,272 shares of the company’s stock valued at $3,676,999,000 after purchasing an additional 541,338 shares during the period. Fisher Asset Management LLC raised its holdings in shares of Johnson & Johnson by 3.8% in the second quarter. Fisher Asset Management LLC now owns 13,118,604 shares of the company’s stock worth $1,591,811,000 after buying an additional 478,982 shares during the period. Swiss National Bank raised its holdings in shares of Johnson & Johnson by 2.7% in the second quarter. Swiss National Bank now owns 9,858,664 shares of the company’s stock worth $1,196,250,000 after buying an additional 257,900 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Johnson & Johnson by 4.5% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,978,198 shares of the company’s stock worth $1,089,415,000 after buying an additional 387,504 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Johnson & Johnson by 9.5% in the first quarter. Dimensional Fund Advisors LP now owns 7,552,034 shares of the company’s stock worth $967,793,000 after buying an additional 654,350 shares during the period. 66.51% of the stock is owned by institutional investors.

JNJ has been the topic of several recent analyst reports. Raymond James increased their price target on Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a report on Wednesday, October 17th. Credit Suisse Group increased their price target on Johnson & Johnson from $149.00 to $152.00 and gave the stock an “outperform” rating in a report on Wednesday, October 17th. Citigroup increased their price target on Johnson & Johnson from $137.00 to $148.00 and gave the stock a “neutral” rating in a report on Monday, October 22nd. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Wells Fargo & Co reiterated an “outperform” rating and issued a $160.00 price target (up from $155.00) on shares of Johnson & Johnson in a report on Wednesday, October 17th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $143.90.

In other Johnson & Johnson news, VP Peter Fasolo sold 166,695 shares of the firm’s stock in a transaction on Tuesday, December 4th. The stock was sold at an average price of $146.41, for a total transaction of $24,405,814.95. Following the transaction, the vice president now directly owns 155,540 shares in the company, valued at approximately $22,772,611.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael E. Sneed sold 30,943 shares of the firm’s stock in a transaction on Friday, November 23rd. The stock was sold at an average price of $142.46, for a total value of $4,408,139.78. Following the transaction, the executive vice president now owns 70,817 shares in the company, valued at $10,088,589.82. The disclosure for this sale can be found here. Insiders have sold a total of 510,544 shares of company stock worth $74,414,877 over the last 90 days. 0.22% of the stock is currently owned by company insiders.

JNJ opened at $145.43 on Friday. The firm has a market cap of $391.46 billion, a price-to-earnings ratio of 18.35, a PEG ratio of 2.28 and a beta of 0.59. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.99. The company has a current ratio of 1.72, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $2.03 by $0.02. The company had revenue of $20.35 billion for the quarter, compared to the consensus estimate of $20.05 billion. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. Johnson & Johnson’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period last year, the business posted $1.90 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 8.16 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be issued a dividend of $0.90 per share. The ex-dividend date is Monday, November 26th. This represents a $3.60 annualized dividend and a yield of 2.48%. Johnson & Johnson’s payout ratio is currently 49.32%.

WARNING: This story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.dailypolitical.com/2018/12/08/lowe-brockenbrough-co-inc-increases-position-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also: Market Capitalization

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.